A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

Abstract

BACKGROUNDCohort studies in Bangladesh showed promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011. METHODSWe conducted a phase 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides. Participants were randomly assigned, in a 2:1 ratio, to receive a short regimen (9 to 11 months) that included high-dose moxifloxacin or a long regimen (20 months) that followed the 2011 WHO guidelines. The primary efficacy outcome was a favorable status at 132 weeks, defined by cultures negative for Mycobacterium tuberculosis at 132 weeks and at a previous occasion, with no intervening positive culture or previous unfavorable outcome. An upper 95% confidence limit for the between-group difference in favorable status that was 10 percentage points or less was used to determine noninferiority. RESULTSOf 424 participants who underwent randomization, 383 were included in the modified intention-to-treat population. Favorable status was reported in 79.8% of participants in the long-regimen group and in 78.8% of those in the short-regimen group -a difference, with adjustment for human immunodeficiency virus status, of 1.0 percentage point (95% confidence interval [CI], −7.5 to 9.5) (P = 0.02 for noninferiority). The results with respect to noninferiority were consistent among the 321 participants in the per-protocol population (adjusted difference, -0.7 percentage points; 95% CI, −10.5 to 9.1). An adverse event of grade 3 or higher occurred in 45.4% of participants in the long-regimen group and in 48.2% in the short-regimen group. Prolongation of either the QT interval or the corrected QT interval (calculated with Fridericia's formula) to 500 msec occurred in 11.0% of participants in the short-regimen group, as compared with 6.4% in the long-regimen group (P = 0.14); because of the greater incidence in the short-regimen group, participants were closely monitored and some received medication adjustments. Death occurred in 8.5% of participants in the short-regimen group and in 6.4% in the long-regimen group, and acquired resistance to fluoroquinolones or aminoglycosides occurred in 3.3% and 2.3%, respectively. CONCLUSIONSIn persons with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides, a short regimen was noninferior to a long regimen with respect to the primary efficacy outcome and was similar to the long regimen in terms of safety.

Ending tuberculosis by 2030—Pipe dream or reality?

“…The duration of treatment for drug-susceptible TB has remained doggedly at 6 months, with attempts to shorten this to 4 months being unsuccessful. In contrast, there have been notable advances in shortening the treatment of multidrug-resistant TB from 24 months to <1 year (Nunn et al, 2019). Ongoing trials with shorter 6-month regimens and using fully oral treatment with drugs such as bedaquiline, delaminid, linezolid, and pretomanid suggest further improvements in the treatment of drug-resistant TB (World Health Organization, 2019b).…”

Clinical Development of New TB Vaccines: Recent Advances and Next Steps

“…By contrast, since the severity and extent of TB disease pathology and the resulting inflammatory milieu are directly related to effectiveness of treatment (Chen et al, 2014), the efficacy of therapeutic and POR vaccines might well be regimenspecific, and different for DR-and DS-TB strains. Whilst clinical trial outcomes for DR-TB have improved (Nunn et al, 2019), historical rates of treatment default, treatment failure, and TB mortality have far exceeded rates of post-treatment TB recurrence (Ahuja et al, 2012), since many DR-TB patients have not survived to cure (Ahuja et al, 2012;Aung et al, 2014). The inactivated mycobacterial vaccine candidate RUTI (Nell et al, 2014), a liposomal formulation of fragmented M. tuberculosis, is planned to enter a double-blind, placebo-controlled trial of safety and immunogenicity in 27 DR-TB patients after 12 or 16 weeks of successful intensive phase treatment (NCT02711735).…”

Advances in clinical trial design: Weaving tomorrow’s TB treatments

“…This situation is more likely to pertain in drug susceptible TB than in drug resistant TB, which, in most settings, has suboptimal results. A noninferiority design was used in the STREAM Stage 1 trial in which the proposed intervention was of substantially shorter duration, which, if demonstrated, would be of considerable benefit to patients and health services, irrespective of whether it was found to be noninferior or superior to the long-duration control [42]. Future trials in drug resistant TB in the next few years may be either of superiority or noninferiority design depending on assumptions regarding the control regimen and the benefits expected from the intervention regimen(s).…”